S-1 vs. paclitaxel plus carboplatin as adjuvant chemotherapy for completely resected stageï¿½II/IIIA non‑small‑cell lung cancer

Okuda, Kunio; Yano, Motoki; Tatematsu, Tsutomu; Nakamae, Katsumi; Yamada, Takeshi; Kasugai, Toshio; Nishida, Tsutomu; Sano, Mitsuru; Moriyama, Satoru; Haneda, Hiroshi; Kawano, Osamu; Nakanishi, Ryoichi

doi:10.3892/mco.2017.1481

Cited by 4 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study was registered on the UMIN Clinical Trial database (ID:000001510). We have reported on details of this study ( 32 ). In this paper, we evaluated the relationships between the protein expression and the prognosis of patients who received adjuvant chemotherapy after complete surgical resection.…”

Section: Methodsmentioning

confidence: 99%

“…The sample size was determined based on a phase II study reported by Kawamura et al ( 39 ) applying docetaxel plus gemcitabine as an adjuvant chemotherapy in 35 patients. The number of patients in each arm was calculated using the Fleming method and found to be 32 per arm ( 32 ). However, sufficient data for patients in the study could not be gathered within the study period.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

The relationship between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase, excision repair cross‑complementation group 1 and class III β‑tubulin, and the therapeutic effect of S‑1 or carboplatin plus paclitaxel in non‑small‑cell lung cancer

et al. 2018

Self Cite

View full text Add to dashboard Cite

Previous studies have reported that the expressions of specific proteins may predict the efficacy of chemotherapy agents for non-small cell lung cancer (NSCLC) patients. The present study evaluated the expression of proteins hypothesized to be associated with the effect of chemotherapeutic agents in 38 NSCLC patients with pathological stage II and IIIA. The subjects received carboplatin plus paclitaxel (CP) or S-1 as adjuvant chemotherapy following complete resection. The protein expressions evaluated were those of thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD) and orotate phsphoribosyltransferase (OPRT), which were suspected to be associated with the effect of S-1 agents, excision repair cross-complementation group 1 (ERCC1), which was suspected to be associated with the effect of platinum-based agents, and class III β-tubulin (TUBB3), which was suspected to be associated with the effect of taxane-based agents. The positive rate of TS was 55.3% (n=21/38), DPD was 57.9% (n=22/38), OPRT was 42.1% (n=16/38), ERCC1 was 47.4% (n=18/38) and TUBB3 was 44.7% (n=17/38). Among the patients who received S-1 adjuvant chemotherapy, TS-negative cases demonstrated a significantly better disease-free survival than positive cases. Thus, TS protein expression may have been a factor that predicted the effect of S-1 agent as adjuvant chemotherapy.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

The relationship between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase, excision repair cross‑complementation group 1 and class III β‑tubulin, and the therapeutic effect of S‑1 or carboplatin plus paclitaxel in non‑small‑cell lung cancer

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

IMRT combined with S-1 concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a prospective phase II study

Wang

et al. 2019

Invest New Drugs

View full text Add to dashboard Cite

Efficacy of carboplatin plus S-1 for the treatment of non-small cell lung cancer

Han

Wei

et al. 2019

Medicine

View full text Add to dashboard Cite

Background: Non-small cell lung cancer (NSCLC) is the most common lung cancer. Numerous clinical studies have reported that the combination of carboplatin and S-1 (CS) can be used to treat NSCLC effectively. However, no systematic review has been conducted to assess its efficacy and safety for NSCLC. This systematic review aims to evaluate the efficacy and safety of CS for treatment of patients with NSCLC. Methods: This study will retrieve the following electronic databases from inception to the February 1, 2019: Cochrane Library, EMBASE, MEDILINE, CINAHL, AMED, and 4 Chinese databases without any language limitations. This systematic review will include randomized controlled trials (RCTs) and case-control studies for assessing the efficacy and safety of CS for the treatment of NSCLC. Cochrane risk of bias will be used as methodological quality assessment for each qualified study. The RevMan V.5.3 software will be utilized to synthesize the data and conduct the meta-analysis if it is allowed. The data will be pooled by using the random-effects model or fixed-effects model. Results: The primary outcome is overall response rate. The secondary outcomes are overall survival, progression-free survival, the disease control rate, and any adverse events. Conclusion: It will provide latest evidence to determine the efficacy and safety of CS for treatment of patients with NSCLC. Ethics and dissemination: No research ethic approval is needed in this study because this study will not analyze individual patient data. The results are expected to disseminate through peer-reviewed journals. Systematic review registration: PROSPERO CRD42019124860.

show abstract

S-1 vs. paclitaxel plus carboplatin as adjuvant chemotherapy for completely resected stageï¿½II/IIIA non‑small‑cell lung cancer

Cited by 4 publications

References 33 publications

IMRT combined with S-1 concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a prospective phase II study

Efficacy of carboplatin plus S-1 for the treatment of non-small cell lung cancer

Contact Info

Product

Resources

About